Array Biopharma, Inc. (ARRY) Posts Q2 Loss of $0.06, Sales Top Expectations
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $7.90 --0%
EPS Growth %: -48.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -48.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $21.76 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Hyperscale Data signs $1.2B AI compute deal for Michigan campus
- JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
